China Pavilion Wows Visitors at Osaka Expo
The China Pavilion consists of three segments: "Harmony between Humanity and Nature" "Green Mountains and Clear Waters" and "Endless Life."
The "Harmony between Humanity and Nature" section highlights China's ancient ecological wisdom, which emphasizes respect and reverence for nature. It features a large multimedia display themed around the 24 solar terms and a digital presentation of Pictures of Tilling and Weaving, the world's earliest agricultural encyclopedia. By using modern technology, it showcases replicas of iconic artifacts such as the oracle bones unearthed in Xiaotun Village, the He Zun, and the copper plates of the imperial edict on unifying weights and measures of the Qin dynasty, as well as key archaeological sites like Sanxingdui, Liangzhu, and Yinxu.
The "Green Mountains and Clear Waters" section explains China's ecological philosophy. Through multimedia installations, it features projects such as the Dujiangyan irrigation system, the world's earliest water conservancy project, the 2,500-year-old mulberry-dike fishpond system and so on.
The "Endless Life" section focuses on China's breakthroughs in deep space exploration, deep sea research and artificial intelligence. Highlights include the first-ever close-up comparison display of soil from the moon's far side and near side, live video interaction between Chinese astronauts in the Tiangong Space Station and expo visitors, a simulated cabin of the Jiaolong deep-sea submersible showing rare footage from 7,062 meters below the sea, and an AI model that brings the beloved mythological figure Sun Wukong to life and discusses past and present topics with visitors, composing poems, and creating art.
The China Pavilion has hosted various events that promote Kunqu Opera and the 24 solar terms, as well as Chinese companies including iFLYTEK and COSCO. In the coming months, dozens of Chinese provinces, regions, and municipalities will bring their amazing exhibits and performances to make the pavilion even a bigger draw.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
13 hours ago
- Korea Herald
Vital Materials Released Quantum Flux Photon Counting CT (PCCT) Full Vertical Integration Technology
BEIJING, Aug. 20, 2025 /PRNewswire/ -- From August 15-17, the 31 st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held in Beijing. Vital Materials officially launched the VITA Genesis, China's fully proprietary Photon Counting CT (PCCT) scanner, marking the entry of global medical imaging technology into the "Quantum Flux" sensing era and empowering Chinese innovation in precision diagnostics and treatment. The Photon Counting Detectors (PCD), as the core technology of PCCT, differ significantly from traditional Energy Integrating Detectors (EID). Traditional CT scanners require X-ray photons to first be converted into visible light, then into electrical signals. In contrast, the PCCT detector employs semiconductor materials, where X-ray photons excite electrons, creating electron-hole pairs proportional to photon energy. Charge carriers from the pairs are separated by an electric field to generate electrical pulses. Application-Specific Integrated Circuits (ASIC) categorize these pulses by energy bins, enabling precise photon counting and energy resolution. This breakthrough provides crucial technical support for multi-energy spectral imaging, significantly enhancing the diagnostic value of medical imaging. Currently, the PCCT detectors primarily utilize three materials: Cadmium Zinc Telluride (CdZnTe or CZT), Cadmium Telluride (CdTe), and Deep Silicon. CZT is emerging as a breakthrough for next-generation medical imaging technology due to its outstanding detection capabilities. The core value of VITA Genesis lies not only in adopting a detector solution based on the CZT, but more importantly in pioneering the mastery of PCCT's full vertical integration technology. This includes ultra-high purity metals purification and compounding, single crystal growth and processing, component design and development, CT system integration, and imaging algorithm development, establishing a global paradigm in the field of PCCT.
Korea Herald
6 days ago
- Korea Herald
Stone in Yunfu: carving timeless beauty through centuries of craftsmanship
GUANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- News report from GDToday. Yunfu, a city in Guangdong Province known as the "Capital of Stone in China," shines as a radiant pearl in the Lingnan region. Every piece of stone here bears the mark of time. With a legacy spanning over four centuries, Yunfu fuses the raw artistry of nature with the brilliance of human craftsmanship, creating a stone culture that has captivated the world. Yunfu is home to a diverse collection of stone, resembling nature's grand palette and showcasing the "essence of global geological evolution". It boasts over a thousand varieties of stone, including marble, granite, and limestone, alongside internationally renowned stones such as Blue Jade from Africa, Crystal from Italy, Snow Mountain Blue, Pandora, Golden Peacock, and Crystal Blue from Brazil. As "China's Stone Circulation Demonstration Base" and "China's Capital of Artificial Stone," Yunfu hosts the annual International Stone Materials Science and Tech Fair and Stone Culture Week, drawing merchants from around the globe and living up to its promise of "global sourcing and global sales." Yunfu hosts China's largest stone industry cluster, with over 4,000 enterprises stretching along the famed "Hundred-Mile Stone Materials Corridor" and 200,000 skilled professionals driving innovation. The simultaneous advancement of eco-friendly production and digital transformation has infused traditional industries with green vitality in the modern era. Today, Yunfu connects with the world through stone. From monumental architectural visions to elegant touches in home design, the stone in Yunfu, carved with centuries of craftsmanship and infused with the spirit of nature, continues to create timeless masterpieces for the global stage. The 22nd Yunfu International Stone Materials Sci-Tech Fair and the 16th Yunfu Stone Cultural Week will be held from October 18 to 21, 2025, at Hall A of the Yunfu International Stone Materials Expo Center at Hekou Subdistrict, Yuncheng District, Yunfu City. This year, the event will feature stone pavilions of fine stone products showcased by stone enterprises. We sincerely invite fellow professionals, designers, and distinguished guests from around the world in the stone industry to participate as exhibitors or visitors. Scan the QR codes to discover more about Yunfu's stone industry.
Korea Herald
06-08-2025
- Korea Herald
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA ® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA ® IV in the United States. [1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). [1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure. [2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: AVTOZMA ® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA ® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment. Contraindications: Known hypersensitivity to tocilizumab products. Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), STEQEYMA ® (ustekinumab-stba), and AVTOZMA ® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA ® (infliximab-dyyb). For more information, please visit Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
